ATOS Atossa Genetics Inc.

1.55
0  0%
Previous Close 1.55
Open 1.51
Price To Book 0.99
Market Cap 14,153,025
Shares 9,130,984
Volume 63,257
Short Ratio
Av. Daily Volume 97,992
Stock charts supplied by TradingView

NewsSee all news

  1. Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

    SEATTLE, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders: To Our Valued Shareholders: I

  2. Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.

    SEATTLE, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast

  3. Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women

    SEATTLE, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast

  4. Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019

    SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast

  5. Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update

    SEATTLE, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data met primary endpoint - June 27, 2019. High dropout rate noted.
Endoxifen
Mammographic breast density (MBD)
Phase 2 trial ongoing - noted December 28, 2017.
Fulvestrant
Cuctal carcinoma in situ(DCIS) - invasive breast cancer
Phase 1 preliminary data September 13, 2018 noted drug met safety and tolerability objectives. Final data January 9, 2019 confirmed objectives met. Program will not be advanced in 2020.
Endoxifen
Male breast cancer and Gynecomastia
Phase 2 continues to enrol - noted January 22, 2020.
Endoxifen
Breast cancer - window of opportunity setting
Phase 2 trial to commence 1Q or 2Q 2020.
Endoxifen - oral
Mammographic breast density (MBD)

Latest News

  1. Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

    SEATTLE, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders: To Our Valued Shareholders: I

  2. Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.

    SEATTLE, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast

  3. Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women

    SEATTLE, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast

  4. Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019

    SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast

  5. Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update

    SEATTLE, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast

  6. Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

    SEATTLE, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast

  7. Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

    SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel

  8. The Dr.Quay.com Website and ElevatorMedicine™ Launch to Promote Breast Cancer Awareness Month

    SEATTLE, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Dr. Steven Quay, MD, PhD, is proud to announce today his participation in National Breast Cancer Awareness Month with the launch of his new website, www.DrQuay.com, dedicated

  9. Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

    SEATTLE, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast

  10. Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

    SEATTLE, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast

  11. Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

    SEATTLE, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast